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Background: Cardiac surgery with cardiopulmonary bypass (CPB) is a known risk factor for acute 
respiratory distress syndrome (ARDS). We aimed to analyze the treatment outcome in patients who required 
veno-venous extracorporeal membrane oxygenation (VV-ECMO) for postcardiotomy ARDS despite other 
rescue modalities.
Methods: We retrospectively reviewed the outcomes in 13 patients (mean age, 54.7±5.9 years) who received 
VV-ECMO support for refractory ARDS after cardiac surgery between March 2013 and February 2016 at 
Severance Hospital, Yonsei University (Seoul, Korea).
Results: At the start of VV-ECMO, the average lung injury score was 3.0±0.2, and the Respiratory 
Extracorporeal Membrane Oxygenation Survival Prediction (RESP) score was −4±1.1. Although 7 patients 
initiated VV-ECMO support within 24 h from operation, the remaining 6 started at a median of 8.5 days 
(range, 5−16 days). Nine (69.3%) patients were successfully weaned from VV-ECMO. After a median 
follow-up duration of 14.5 months (range, 1.0−33.0 months) for survivors, the 1-year overall survival was 
58.6%±14.4%. The differences in the overall survival from VV-ECMO according to the RESP score risk 
classes were borderline significant (100% in class III, 50%±25% in class IV, and 20%±17.9% in class V; 
P=0.088).
Conclusions: VV-ECMO support can be a feasible rescue strategy for adult patients who develop 
refractory ARDS after a cardiac surgery. Additionally, the RESP score seems a valuable prognostic tool for 
post-ECMO survival outcome in this patient population as well.
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Introduction
Acute respiratory distress syndrome (ARDS) is a life-
threatening pulmonary condition that can lead to rapidly 
progressive respiratory failure (1). Cardiac surgery under 
cardiopulmonary bypass (CPB) is a well-recognized risk 
factor of ARDS (2,3). CPB is known to trigger severe 
systemic inflammatory response, and abnormal cytokine 
release is known to be related to the interaction of blood 
components with the artificial surface of the CPB, surgical 
trauma, abnormal shear stress, and ischemia-reperfusion 
injury upon aortic declamping (4-6). Moreover, allogeneic 
blood product transfusions in patients undergoing cardiac 
surgery render them prone to transfusion-related acute 
lung injury (7). Other causes of postcardiotomy respiratory 
failure include ventilator-associated pneumonia, temporary 
cardiac dysfunction, systemic hypothermia, catecholamine 
infusions, and ventilator-induced lung injury (3,8).
Managements including lung protective ventilation 
strategy, strict fluid balance, and early use of neuromuscular 
blockade have demonstrated their efficacy (3). However, in 
the face of a rapid ARDS progression to a life-threatening 
hypoxemia, which is usually the case in post-cardiac surgical 
setting, prompt application of rescue therapies are often 
indicated to sustain life. For refractory severe ARDS, 
recruitment maneuvers, nitric oxide inhalation, or prone 
positioning may transiently improve oxygenation. However, 
evidence of safety and effectiveness of these treatments in 
patients of recent open-heart surgery is limited, and survival 
benefits have rarely been reported.
Over the past 2 decades, veno-venous extracorporeal 
membrane oxygenation (VV-ECMO) support  has 
emerged as a valuable rescue therapy to facilitate 
respiratory recovery in refractory ARDS to conventional 
therapy (9). With technical improvements in modern 
ECMO (10-12) and several recent clinical data reporting 
encouraging survival after VV-ECMO for adult patients 
with respiratory failure (13,14), the application of VV-
ECMO is sharply increasing in broader clinical conditions 
(12,15,16). Although the identification of patients at high 
risk for postcardiotomy ARDS remains an area of active 
investigation (2,8,17,18), the standard management is 
not decided yet. The use of VV-ECMO for respiratory 
failure after thoracic surgery has increased and is known 
to improve survival in patients with ARDS perioperatively. 
Veno-arterial ECMO (VA-ECMO) therapy could be 
valuable for patients with postcardiotomy cardiac failure. 
We aimed to analyze the treatment outcome in patients 
who required VV-ECMO support for postcardiotomy 
ARDS despite other rescue modalities.
Methods
Patients
A total of 2,234 patients underwent cardiac surgery at 
Severance Cardiovascular Hospital, Yonsei University 
College of Medicine, between March 2013 and February 
2016. From a retrospective review of the ECMO database in 
our intensive care unit (ICU), we identified 13 adult patients 
who received VV-ECMO for development of refractory 
ARDS after cardiac surgery under CPB. We excluded 
patients who died on the day of surgery. Preoperative and 
postoperative data as well as laboratory and respiratory data 
at the initiation and during ECMO therapy were obtained 
using a retrospective review of the prospectively recorded 
registry database and electronic medical records. This study 
was approved by the institutional review board of Yonsei 
University Health Service, Severance Hospital, and was 
conducted in accordance with the Declaration of Helsinki.
Indication of veno-venous extracorporeal membrane 
oxygenation (VV-ECMO)
All study patients were transferred to the cardiovascular 
surgical  ICU with endotracheal intubation under 
mechanical ventilation support after surgery. Arterial blood 
gas analysis was routinely examined perioperatively and 
immediately upon ICU admission. Blood pressure and 
sugar level were strictly monitored. In patients developing 
postoperative respiratory failure, an attempt to improve 
oxygenation with conventional ventilation is generally 
undertaken including optimizing positive end-expiratory 
pressure (PEEP) level or prone positioning. Nitric oxide 
was not used per institutional policy. If stabilization efforts 
were not successful after several hours and the patient had 
severe hypoxemia with a partial pressure of arterial oxygen-
to-fraction of inspired oxygen ratio (PaO2/FiO2) ≤85 mmHg 
and PEEP ≥5 cmH2O or if uncompensated respiratory 
acidosis with pH ≤7.15 combined with new bilateral 
pulmonary infiltrates on chest radiograph persisted, VV-
ECMO was considered. All but 1 patient (patient 3) met the 
criteria for severe ARDS based on the Berlin definition (19) 
at the time of VV-ECMO implantation. Patient 3 who had 
underlying chronic obstructive pulmonary disease required 
VV-ECMO for acute exacerbation of chronic obstructive 
pulmonary disease with uncontrolled respiratory acidosis 
(pH 7.15).
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Implantation and management of veno-venous 
extracorporeal membrane oxygenation (VV-ECMO)
All VV-ECMOs were performed with percutaneous 
cannulation by trained cardiovascular surgeons. The 
femoral vein was directly cannulated after limited cut-
down using the Seldinger technique to introduce a 21 F 
venous cannula (DLP Medtronic, Minneapolis, MN, USA), 
with the tip positioned in the inferior vena cava at the 
entrance of the right atrium for drainage. The oxygenated 
blood was returned through a 17 F arterial cannula (DLP 
Medtronic) in the right internal jugular vein with the 
tip positioned in the superior vena cava just before the 
entrance to the right atrium. The rest of the ECMO circuit 
consisted of a centrifugal pump oxygenator with hollow-
fiber polymethylpentene membrane heparin-bound surface 
using a PLS bypass system (MAQUET; Cardiopulmonary 
AG, Hechingen, Germany; n=9) or with Xcoating Capiox 
emergent bypass system (Terumo, Tokyo, Japan; n=4).
The sweep gas flow was set to maintain a PaCO2 target 
of 35−45 mmHg under lung rest ventilation strategy. The 
target ECMO blood pump speed was 3.0−4.5 L/min. 
Systemic anticoagulation with unfractionated heparin was 
titrated to maintain an activated clotting time between 
160 and 220 s, but heparin was replaced by argatroban 
in 1 patient (patient 10) who developed heparin-induced 
thrombocytopenia. Supplement of coagulation factors or 
platelets were applied as indicated by laboratory coagulation 
analysis. Under VV-ECMO, the general targets of lung-
protective ventilation were tidal volumes of 3−5 mL/kg 
predicted body weight, respiratory rate of 12−16/min, and 
a plateau inspiratory pressure <25 cmH2O with low FiO2 
(≤60%). The PEEP was set at 6−10 cmH2O, but it could 
be changed at the discretion of the physician according to 
patients’ status. 
Veno-venous extracorporeal membrane oxygenation (VV-
ECMO) weaning
In patients with improvement of lung functions evident in 
hemodynamic, clinical, and respiratory measurements, ECMO 
flow was gradually reduced by approximately 0.5 L/min 
at a time. When adequate oxygenation was sustained with 
moderate ventilator settings (FiO2 <0.6, PEEP <10 mmHg, 
peak inspiratory pressure <25 cmH2O, and respiratory rate 
<40/min) for at least 4 h, VV-ECMO was stopped. VV-
ECMO weaning was determined successful if patients 
survived at least 72 h after ECMO removal.
Statistical analysis
Continuous variables were analyzed by Mann-Whitney 
U test and were demonstrated as mean ± standard error 
or median with range. Categorical data were analyzed by 
Fisher’s exact test, and these data were shown as absolute 
frequencies and percentages. The overall survival curve 
after implementation of ECMO was plotted using the 
Kaplan-Meier method, and differences were evaluated using 
the log-rank test. Two-sided P values <0.05 were considered 
statistically significant. Statistical analyses were performed 
using the Statistical Package for the Social Sciences version 
16.0 software (SPSS Inc., Chicago, IL, USA).
Results
Patient baseline characteristics
During the study period, 13 adult patients (mean age, 
54.7±5.9 years) underwent VV-ECMO for ARDS after 
cardiac surgery under CPB. The characteristics of the 
study population are listed in Table 1. Patient 9 had 
undergone previous ascending aorta replacement for aortic 
dissection, and patient 3 had undergone a redo mitral 
valve replacement. The surgeries included coronary artery 
bypass graft (CABG; n=1), CABG with valvular operation 
(n=1), valvular operation (n=6), and emergent heart 
transplantation (HT; n=5). Four of the 8 non-HT surgeries 
were emergent operations for 3-vessel coronary artery 
disease (n=2) or severe aortic stenosis (n=2). Indications for 
HT were acute myocarditis (n=2), dilated cardiomyopathy 
with mitral regurgitation (n=1), congestive heart failure 
after ascending aorta replacement for aortic dissection (n=1), 
and acute myocardial infarction with cardiac arrest (n=1), 
as shown in Table 1. Preoperative VA-ECMO support as 
a bridge therapy was required in all 5 HT patients with a 
median preoperative interval of 6 days (range, 2−8 days). 
Four (80%) of these patients survived cardiac arrest after 
cardiopulmonary resuscitation. An underlying chronic 
obstructive pulmonary disease was noted in 2 patients.
Extracorporeal membrane oxygenation (ECMO) institution
The mean CPB duration (206±22 vs. 150±20 min; P=0.107) 
and aortic cross-clamping time (123±11 vs. 83±6 min; 
P=0.007) were longer in patients with HT (data not shown). 
All but 1 patient among the 8 non-HT patients were 
weaned from CPB without difficulty or inotropes. Patient 
5 who had received an isolated CABG under CPB for acute 
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myocardial infarction with cardiogenic shock required intra-
aortic balloon pump administration during a re-exploration 
for pleural space bleeding, and the configuration of the 
preoperative VA-ECMO was switched to VV-ECMO 
due to severe hypoxemia. Patient 11 also underwent re-
exploration for aortomy site bleeding on postoperative day 1, 
which was controlled successfully. The median interval to 
VV-ECMO from cardiac surgery among the 8 non-HT 
patients was 7.5 days (range, 1–16 days). All 5 HT patients 
initiated VV-ECMO before being transferred to the ICU.
The clinical characteristics at the time of VV-ECMO 
initiation are described in Table 2. Six patients were 
receiving continuous veno-venous hemodiafiltration. The 
mean lung injury score and Acute Physiology and Chronic 
Health Evaluation (APACHE) II score at VV-ECMO 
implantation were high (3.0±0.2 and 28.2±2.2, respectively), 
reflecting severe disease. We also used the recently proposed 
prognostic scoring system, the Respiratory Extracorporeal 
Membrane Oxygenation Survival Prediction (RESP) 
score (20), in our study patients (Table 2).
Extracorporeal membrane oxygenation (ECMO) and 
survival outcomes
VV-ECMO weaning was successful in 9 (69%) of the 
13 patients. The median duration of VV-ECMO in these 
patients were 7.2 days (range, 3−16 days). VV-ECMO 
reimplantation was not observed. The average amounts of 
transfusions were 12.6±2.8 units of red blood cell, 53.8± 
13.4 units of platelets, and 6.4±2.5 fresh frozen plasma. 
Non-survivors received significantly larger amounts of 
post-ECMO platelet transfusions (67.2±23.3 vs. 45.4±16.9; 
P=0.037). After a median follow-up duration of 14.5 months 
(range, 1.0−33.0 months) for survivors, the 1-year overall 
survival was 58.6%±14.4%. Overall, in-hospital mortality 
was 46.1%. Six patients, including 2 successfully weaned 
cases (patient 8 and patient 9), died during their ICU stay 
after a median of 5.5 days (range, 1−35 days) after ECMO 
implantation and a median of 26 days (range, 1−201 days) 
after cardiac surgery. Four were HT patients, and septic 
shock from fungal (n=4) or bacterial (n=2) bloodstream 
infections accounted for all cause of deaths in the present 
series. Patient 9 had achieved successful ECMO weaning 
but died of disseminated aspergillosis with concomitant 
critical neuromyopathy and consequent prolonged 
mechanical ventilation. Patient 11 had ischemic colitis on 
postoperative day 9, necessitating descending colectomy 
with colostomy, which was responsible for the fungemia 
(Table 1). Major ECMO-related complications such as leg 
ischemia were not observed in our patient cohort. All 7 
(54%) hospital survivors were currently alive at median 
follow-up of 16 months (range, 7−34 months).
Survivors  (n=7)  and non-survivors  (n=6)  were 
comparable for age, sex, body mass index, comorbidities, 
and both additive and logistic EuroScores, as shown in 
Table 2. However, non-survivors required higher units of 
perioperative blood transfusions, had longer aortic cross-
clamping time, and had higher APACHE II score and 
lactate level at ECMO initiation, but did not reach statistical 
significance. Interestingly, the only pre-ECMO prognostic 
factor for survival was the RESP score. The risk classes 
according to the total RESP score were class III (scores −1 
to 2) in 4 patients, class IV (scores −5 to −2) in 4 patients, 
and class IV (scores ≤6) in 5 patients. All non-survivors were 
classified as risk class IV or V, and the mean RESP score was 
significantly lower (−7±1.4) compared to that of the survivors 
(−1.4±1.0; P=0.01). As shown in Figure 1, the differences in 
the Kaplan-Meier survival from VV-ECMO initiation after 
cardiac surgery according to the RESP risk classes were 
identified with a borderline significance (100% in class III, 
50%±25% in class IV, and 20%±17.9% in class V; P=0.088).
Discussion
Despite the advances in CPB techniques and in the 
preventive measures of respiratory complications after 
cardiac surgery (8,21), postoperative ARDS manifests in 
10−20% of patients who undergo cardiac surgery (2), and 
its overall mortality remains high (3,18,22). According to a 
recent literature review on ARDS after cardiac surgery (22), 
the mortality rate varied from 15% to 92%, suggesting a 
heterogeneity in the study populations, varied definitions 
used to identify ARDS, and different managements. 
Optimized mechanical ventilation in line with the ARDS 
network is a key priority for physicians in managing 
ARDS (23), and this lung-protective ventilation strategy 
of limiting tidal volume to 6−8 mL/kg predicated body 
weight while keeping the plateau airway pressure below 
30 cmH2O is of particular importance for patients receiving 
cardiac surgery under CPB, in whom excessive systemic 
inflammation has already been induced by intraoperative 
extracorporeal circulation (3,24,25). According to a recent 
study on 3,434 patients receiving cardiac surgery by 
Lellouche et al. (26), the use of tidal volumes >12 mL/kg 
predicted body weight during the postoperative period 
was associated with prolonged mechanical ventilation and 
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Table 2 Comparison of survivors and nonsurvivors at the time of VV-ECMO
Characteristics All (n=13) Survivor (n=7) Non-survivor (n=6) P value
Age, years 54.7±5.9 54.4±6.7 55.3±13.6 0.643
Men, n (%) 8 (61.5) 4 (57.1) 4 (66.7) 1.000
Body mass index (kg/m2) 24.7±1.7 26.3±2.1 21.1±2.4 0.217
Comorbidities, n (%)
COPD 2 (15.4) 2 (28.6) 0 (0) 0.462
Asthma 1 (7.7) 0 (0) 1 (16.7) 0.462
Hypertension 2 (15.4) 2 (28.6) 0 (0) 0.462
Diabetes mellitus 1 (7.7) 1 (14.3) 0 (0) 1.000
Dyslipidemia 2 (15.4) 1 (14.3) 1 (16.7) 1.000
History of cerebral infarction 3 (23.1) 1 (14.3) 2 (33.3) 0.559
Cardiac characteristics, n (%) 
Preoperative atrial fibrillation 2 (15.4) 1 (14.3) 1 (16.7) 1.000
Severe pulmonary hypertension 4 (30.8) 2 (28.6) 2 (33.3) 1.000
Previous cardiac surgery 2 (15.4) 1 (14.3) 1 (16.7) 1.000
s/p (status post) AMI 3 (23.1) 1 (14.3) 2 (33.3) 0.559
s/p PCI 1 (7.7) 0 (0) 1 (16.7) 0.462
Additive EuroScore 33.5±7.1 23.9±7.0 44.7±12.1 0.199
Logistic EuroScore 18.8±5.4 11.5±5.4 27.3±9.2 0.153
Ejection fraction, % 37.7±7.2 38.7±8.1 35.5±16.9 0.537
Emergency indication, n (%) 9 (69.2) 4 (57.1) 5 (83.3) 0.559
Preoperative VA-ECMO, n (%) 5 (38.5) 2 (28.6) 3 (50.0) 0.592
Preoperative CRRT, n (%) 6 (46.2) 2 (28.6) 4 (66.7) 0.286
Preoperative CPR, n (%) 5 (38.5) 2 (28.6) 3 (50.0) 0.592
Preoperative ventilation, n (%) 5 (38.5) 1 (14.3) 4 (66.7) 0.103
Cardiopulmonary bypass time 172.0±16.4 166.7±21.1 178.2±27.7 0.886
Aortic cross-clamp time 98.5±7.8 84.7±6.6 114.7±12.5 0.063
Postoperative lactate, mmol/L 7.2±1.6 4.6±1.1 10.3±2.7 0.086
Pre-ECMO ventilation time, days 7.2±1.2 6.4±2.1 8.2±1.0 0.221
Pre-ECMO neuromuscular blockade 9 (69.2) 4 (57.1) 5 (83.3) 0.559
Pre-ECMO bicarbonate 8 (61.5) 3 (42.9) 5 (83.3) 0.266
Pre-ECMO risk scores
APACHE II score 28.2±2.2 25.9±2.8 30.8±3.4 0.198
Lung injury score 3.0±0.2 2.9±0.3 3.0±0.2 1.000
Table 2 (continued)
1810 Song et al. Use of VV-ECMO in postcardiotomy ARDS
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2016;8(7):1804-1813jtd.amegroups.com
increased risk of organ failure.
Despite these backgrounds, in some patients with 
severe ARDS, adequate oxygenation can only be achieved 
using aggressive, non-protective ventilation. To obviate 
ventilation-induced lung injury while ensuring adequate 
oxygen delivery to vital organs, timely application of 
ECMO should be considered. Whereas the use of VA-
ECMO for refractory cardiovascular dysfunction after 
cardiac surgery has been well described in literature 
demonstrating its efficacy as a bridge to recovery (27-29), 
there is paucity of data on the use of postcardiotomy VV-
ECMO for postoperative life-threatening respiratory 
dysfunction. VA-ECMO should be avoided in patients with 
respiratory failure without cardiac failure or refractory 
shock due to many potential complications, including 
systemic thromboembolism, differential hypoxia from 
maldistribution of oxygen, and left ventricular distention 
leading to pulmonary edema and aggravation of pulmonary 
injury (12,30).
We report herein the largest series of adult patients who 
received VV-ECMO after cardiac surgery under CPB in the 
context of postoperative refractory ARDS. We documented 
Table 2 (continued)
Characteristics All (n=13) Survivor (n=7) Non-survivor (n=6) P value
Total RESP Score −4.0±1.1 −1.4±1.0 −7.0±1.4 0.010
Risk class III (−1 to +2) 4 (30.8) 4 (57.1) 0 (0)
Risk class IV (−5 to −2) 4 (30.8) 2 (28.6) 2 (33.3)
Risk class V (≤−6) 5 (38.4) 1 (14.3) 4 (66.7) 0.022
Pre-ECMO transfusion
Red blood cells 9.9±2.1 6.6±1.9 15.2±3.7 0.151
Platelets 27.8±6.3 22.1±8.7 36.8±8.2 0.062
Fresh frozen plasma 9.2±2.2 9.3±3.6 9.2±0.5 0.249
Central venous pressure at ECMO, mmHg 12.5±1.0 11.6±1.0 13.5±1.7 0.377
Laboratory parameters at ECMO
PaO2, mmHg 58.2±5.9 61.2±10.6 54.8±4.5 1.000
FiO2, % 83±4 80±6 87±5 0.375
PaO2/FiO2, mmHg 72±8 79±15 64±6 0.475
PaCO2, mmHg 44.0±5.8 51.8±6.8 42.4±4.5 0.391
PEEP, cmH2O 7.6±1.1 7.6±1.1 8.0±0.9 0.884
pH 7.35±0.03 7.36±0.04 7.34±0.04 0.668
SaO2, % 83±3 82±5 83±3 0.668
Tidal volume, mL 360±28 347±32 375±50 0.668
Lung compliance, mL/cmH2O 4.9±1.2 19.7±3.0 20.5±2.6 0.886
C-reactive protein, mg/L 134±24 140±39 128±27 0.668
Serum creatinine, mg/dL 1.7±0.3 1.6±0.5 1.9±0.3 0.253
Lactate, mmol/L 4.9±1.2 4.0±1.5 6.0±2.0 0.352
Data are the mean value ± standard error of the mean. COPD, chronic obstructive lung disease; AMI, acute myocardial infarction; 
PCI, percutaneous coronary intervention; VA-ECMO, veno-arterial extracorporeal membrane oxygenation; CRRT, continuous renal 
replacement therapy; CPR, cardiopulmonary resuscitation; APACHE, Acute Physiology and Chronic Health Evaluation; RESP, Respiratory 
Extracorporeal Membrane Oxygenation Survival Prediction; PaO2, partial pressure of arterial oxygen; FiO2, fraction of inspired oxygen; 
PaCO2, partial pressure of arterial carbon dioxide; PEEP, positive end-expiratory pressure; SaO2, arterial oxygen saturation
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that VV-ECMO was a feasible rescue therapy for adult 
patients with life-threatening ARDS after cardiac surgery 
under CPB. Although significant morbidity associated with 
VV-ECMO was not observed in the present case series, 
successful weaning from VV-ECMO was possible in 69% 
of the 13 study cases. Not surprisingly, survival outcome 
was less satisfactory among the HT cases (n=5) in whom the 
hospital discharge rate was only 20%, whereas 75% of the 
non-HT cases (n=8) achieved a long-term survival outcome. 
Recently, several investigator groups have developed 
prognostic models aimed to facilitate the identification of 
high-risk populations for ARDS. Gajic et al. (2) developed 
the LIPS model by including both medical and surgical 
patients with ARDS for analysis. Kor et al. (31) proposed the 
surgical lung injury prediction (SLIP) model for use in an 
elective surgical population. More recently, the SLIP-2 score, 
the refined SLIP model (18), was developed and suggested 
a better prognostic value in identifying patients at high 
risk of ARDS in a higher-risk surgical population. All these 
efforts will help minimize the incidence of postoperative 
ARDS and its severity. In our study, CPB time, a known 
variable prognostic of postcardiotomy ARDS and survival 
(3,21,22,24,25), was not significantly different between 
survivors and non-survivors, whereas the aortic cross-
clamping time tended to be longer in the non-survivors, as 
suggested by others (32).
Meanwhile, prognostic factors for post-VV-ECMO 
survival outcomes in refractory ARDS after cardiac surgery 
have not been yet reported. Recently, Schmidt et al. (20) 
published a novel mortality prediction model called the 
RESP score, developed from ECMO data of >2,000 patients 
from the ELSO registry. Klinzing et al. (33) recently 
reported a better performance of this score compared to 
the Predicting Death for Severe Acute Respiratory Distress 
Syndrome on Veno-venous Extracorporeal Membrane 
Oxygenation score in their external validation on 51 patients 
receiving VA-ECMO or VV-ECMO support. Even in 
our present small series, the RESP score was significantly 
associated with survival outcomes. Although all 13 cases 
were classified as classes III–V, large differences in overall 
survival according to the class were observed, although only 
borderline significance was demonstrated. 
The major limitation of our study is the retrospective 
study design and the challenge of meaningful statistical 
significance. Because of the small number of patients, no final 
conclusion can be drawn from the performance of the RESP 
score in our study. The decision for timely application of 
ECMO support in the context of postcardiotomy respiratory 
failure remains difficult and should be determined based 
on individual considerations because ECMO support is 
associated with high morbidity. In this context, our data may 
suggest that the RESP score can be useful in the prediction 
of post-ECMO survival outcomes in a diverse patient 
population.
In conclusion, VV-ECMO seems a feasible bridging 
therapy for injured lung to recover in severe refractory 
ARDS after cardiac surgery under CPB. As all deaths 
occurred after septic shock from bloodstream infection 
acquired during ECMO, knowledge of high-risk patients (i.e., 
HT recipients) and common causal organisms may enhance 
strategies to prevent and control infectious consequence 
and increase post-ECMO survival. Although the prognostic 
value of the RESP score risk classification validated in this 
study should be interpreted with caution, given the relatively 
small number of patients, the RESP score seems a valuable 
tool for physicians to carefully balance the high perioperative 
morbidity and resource use in ECMO treatment against the 
probability of survival.
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